Business Wire

Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse

17.5.2022 17:00:00 EEST | Business Wire | Press release

Share

Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire)

“We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster with LDA’s flexible financing package. We are sure that the relationship with LDA will continue in a mutually gratifying way in the medium and long term horizon, allowing the horses in our stable to become unicorns.”

This new capital commitment of funding will be used to scale Enry’s Island phygital capabilities. Specifically, the areas that the company will focus on are:

  • Expansion in the Metaverse and physical spaces (thanks to Enry’s Island portfolio company Rinascimento 5)
  • International reach increase, thanks to Enry’s Island Local Companies
  • Add 12x to 36x financial value within 3-5 years
  • Consolidating a worldwide standard protocol for the assessment and evaluation of the startups, based on Enry’s Model intellectual property (IP)

At the forefront of the industry, Enry’s Island is the first Incubation & Acceleration Metaverse (# 1 incubator & accelerator in Italy, & # 6 in Europe according to Crunchbase Q4/2021), with local companies in US, UK, Italy, Spain, Ireland, Africa, a global community of more than 800 stakeholders who include entrepreneurs, investors, and professionals and 30 startups, thoroughly assessed and evaluated based on Enry’s Model, the patented intellectual property the whole organization, processes and tool of Enry’s Island is based on. The Enry’s Model is also part of the “Enry’s Theory” manual of business management, published by MacGraw-Hill.

About LDA Capital

LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com; For inquires please email: info@ldacap.com.

About Enry’s Island

  • 15 years of experience in the management of very early stage startups, with a mortality rate of only 10% (against 90% which is the industry average)
  • 12-month incubation and acceleration programs, totally customized to the needs of startups, with investments of € 200k in operational services (not just mentorship)
  • Proprietary patent, Enry's Model, which allows for the evaluation of company performance and value; Enry's Model is also the subject of a McGrawHill manual (which, in view of its success in Europe, has been translated for the US market);
  • Explosive scale up in the last 3 years, going from 8 to 25 companies, from €2M to €40M in portfolio value, from a community of 30 to 800 stakeholders;
  • full remote and totally distributed organization, which has allowed Enry’s Island to grow during the last 2 years of pandemic;
  • A revolutionary corporate architecture, which includes local companies in Ita, US, UK, Africa, Ibiza, Ireland and upcoming openings in the Far East, that do not replicate, but specialize and scale the different EI best practices in the different countries.
  • High information symmetry, given that the whole EI community uses a revolutionary Saas platform (hui.land), which guarantees efficiency and effectiveness in business management and business risk containment; HUI provides KPIs to all internal and external stakeholders, allowing investors to invest directly in target companies through HUI (thanks to crowdfunding campaigns in Europe, US and Canada), directly through HUI;
  • A revolutionary vision and management of space, both physical (having eliminated any physical location, as if it were in a DAO, but using a network of hosts with ideal characteristics for remote working in places with a high quality of life, such as villages, natural areas) and metaverse space (EI has started investing in the metaverse, building its first building in Cryptovoxels and having launched the first investor day entirely in metaverse https://www.cryptovoxels.com/parcels/7328)

Visit www.enrysisland.com and discover why Enry’s Island has ignited interest from all over the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor relations:
Enry’s Island - Benefit Company
Gabriele Vedani
Investor Relations Manager
gabriele.vedani@enrysisland.com
0039 335 6625055
website: enrysisland.com
website: metaverse.enrysisland.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye